TY - JOUR
T1 - Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
AU - Hindsø, Morten
AU - Martinussen, Christoffer
AU - Svane, Maria Saur
AU - Veedfald, Simon
AU - Gade-Rasmussen, Birthe
AU - Hansen, Torben
AU - Madsbad, Sten
N1 - © EFIM 2021.
PY - 2021/3/31
Y1 - 2021/3/31
N2 - UNLABELLED: Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months' follow-up.LEARNING POINTS: Genetic testing is important in patients with neonatal diabetes.Sulfonylurea is the standard treatment for patients with the most common mutation (KCNJ11).We present the novel use of a GLP-1 receptor agonist as effective add-on therapy in a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy.
AB - UNLABELLED: Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months' follow-up.LEARNING POINTS: Genetic testing is important in patients with neonatal diabetes.Sulfonylurea is the standard treatment for patients with the most common mutation (KCNJ11).We present the novel use of a GLP-1 receptor agonist as effective add-on therapy in a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85150263931&partnerID=8YFLogxK
U2 - 10.12890/2021_002352
DO - 10.12890/2021_002352
M3 - Journal article
C2 - 33869096
SN - 2284-2594
VL - 8
SP - 1
EP - 4
JO - European journal of case reports in internal medicine
JF - European journal of case reports in internal medicine
IS - 3
M1 - 002352
ER -